Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Genor Biopharma Holdings's share price is €0.336.
Genor Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €0.06. Hence, Genor Biopharma Holdings's PS Ratio for today is 6.00.
The historical rank and industry rank for Genor Biopharma Holdings's PS Ratio or its related term are showing as below:
FRA:67N0'
s PS Ratio Range Over the Past 10 Years
Min: 3.68 Med: 44.25 Max: 914
Current: 6
During the past 7 years, Genor Biopharma Holdings's highest PS Ratio was 914.00. The lowest was 3.68. And the median was 44.25.
FRA:67N0's PS Ratio is not ranked
in the Biotechnology industry.
Industry Median: 9.22
vs FRA:67N0: 6.00
During the past 7 years, Genor Biopharma Holdings's highest 3-Year average Revenue per Share Growth Rate was 10.10% per year. The lowest was 10.10% per year. And the median was 10.10% per year.
Back to Basics: PS Ratio
Genor Biopharma Holdings (FRA:67N0) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genor Biopharma Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genor Biopharma Holdings PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genor Biopharma Holdings's PS Ratio distribution charts can be found below:
* The bar in red indicates where Genor Biopharma Holdings's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Genor Biopharma Holdings's Share Price of today is €0.336.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Genor Biopharma Holdings's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2025 was €0.06.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Genor Biopharma Holdings (FRA:67N0) has a PS Ratio of 6.00 as of Jul. 23, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genor Biopharma Holdings and its competitors. This is 86% below median its historical median of 44.25. Over the past decade, Genor Biopharma Holdings' PS Ratio has ranged from 3.68 to 914.00.
Is Genor Biopharma Holdings' PS Ratio too high?
Genor Biopharma Holdings' current PS Ratio of 6.00 is 86% below median its 10-year median of 44.25. Over the past 10 years, this metric has ranged from a low of 3.68 to a high of 914.00. The Biotechnology industry median PS Ratio is 9.22. Genor Biopharma Holdings' value of 6.00 is 34.9% below this industry median. Overall, Genor Biopharma Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Genor Biopharma Holdings' PS Ratio compare to VRTX and REGN?
Genor Biopharma Holdings' PS Ratio of 6.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.22. Genor Biopharma Holdings' value of 6.00 is 34.9% below this benchmark. Historically, Genor Biopharma Holdings' own PS Ratio has ranged from 3.68 to 914.00 over the past decade. While the company's 10-year median is 44.25 vs. the industry median of 9.22, Genor Biopharma Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.22, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genor Biopharma Holdings's current PS Ratio of 6.00 is 34.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Genor Biopharma Holdings and its competitors. For the Biotechnology industry, the median PS Ratio is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genor Biopharma Holdings's current PS Ratio is 6.00, which is 86% below median its own 10-year median of 44.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genor Biopharma Holdings stock overvalued right now?
Genor Biopharma Holdings (FRA:67N0) has a current PS Ratio of 6.00. The current PS Ratio is 6.00, which is 86% below median its 10-year median of 44.25 and 34.9% below the Biotechnology industry median of 9.22. Genor Biopharma Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Genor Biopharma Holdings (FRA:67N0), the current PS Ratio is 6.00 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Genor Biopharma Holdings Ltd is a commercial-ready biopharmaceutical company focusing on developing and commercializing oncology and autoimmune drugs. The company is focused on therapeutic areas with substantial unmet medical needs in oncology, autoimmune, and other chronic diseases. Its key drug candidates includes GB491 (lerociclib), a differentiated oral CDK4/6 inhibitor; GB221, a novel HER2 mAb drug candidate; geptanolimab (GB226), GB492, a STING agonist expected to exert synergistic effects in combination with GB226; GB242, an infliximab (Remicade) biosimilar; and GB223, a RANKL, and others.
22GF Score
Get the complete analysis for FRA:67N0
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:67N0 has been successfully added to your 
